Determinants of selective cyclooxygenase-2 inhibitor prescribing: Are patient or physician characteristics more important?

American Journal of Medicine

Volumn 115, Issue 9, 2003, Pages 715-720

  Solomon, Daniel H ^a   Schneeweiss, Sebastian ^a,b   Glynn, Robert J ^a   Levin, Raisa ^a   Avorn, Jerry ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEMOGRAPHY; DRUG SELECTIVITY; DRUG USE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICARE; MODEL; PATIENT; PEPTIC ULCER; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR;

EID: 0347418227     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2003.08.025     Document Type: Article

References (17)

1. Juni P., Rutjes A.W.S., Dieppe P.A. Are selective COX-2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ. 324:2002;1287-1288.
2. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study. A randomized controlled trial. JAMA. 343:2000;1520-1528.
3. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 343:2000;1520-1528.
4. Gabriel S.E., Jaakkimainen L., Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs a meta-analysis . Ann Intern Med. 115:1991;787-796.
5. Silverstein F.E., Graham D.Y., Senior J.R., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo controlled trial. Ann Intern Med. 123:1995;241-249.
6. Lanza F.L. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol. 93:1998;2037-2046.
7. Guidelines for the management of rheumatoid arthritis. 2002 update. Arthritis Rheum. 46:2002;328-346.
8. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 45:1992;613-619.
9. Hosmer D.W., Lemeshow S. Applied Logistic Regression. 2nd ed :2000;162 John Wiley and Sons, New York, New York.
10. D'Agostino R.B., Grundy S., Sullivan L.M., et al. Validation of the Framingham coronary heart disease prediction scores results of a multiple ethnic groups investigation . JAMA. 286:2001;180-187.
11. Nagelkerke N.J.D. A note on a general definition of the coefficient of determination. Biometrika. 78:1991;191-692.
12. Gatsonis C.A., Epstein A.M., Newhouse J.P., Normand S.L., McNeil B.J. Variations in the utilization of coronary angiography for elderly patients with acute myocardial infarction. An analysis using hierarchical logistic regression. Med Care. 33:1995;625-642.
13. Fitzgerald G.A., Patrono C. Drug therapy the coxibs, selective inhibitors of cyclooxygenase-2 . N Engl J Med. 345:2001;433-442.
14. Hrachovec J.B., Mora M. Reporting of 6-month versus 12-month data in a clinical trial of celecoxib. JAMA. 286:2001;2398.
15. Peterson M. Two big selling arthritis drugs are questioned. New York Times. June 4, 2002.
16. Smalley W., Stein C.M., Arbogast P.G., Eisen G., Ray W.A., Griffin M. Underutilization of gastroprotective measures in patients taking nonsteroidal antiinflammatory drugs. Arthritis Rheum. 46:2002;2195-2200.
17. Singh G, Ramey DR. NSAID induced gastrointestinal complications: The ARAMIS perspective - 1997. J Rheumatol. 1998;25(suppl 51):8-16.